- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Business Development Office
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel mucolytics for the treatment of respiratory diseases
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Targeting minor class splicing
- Partnerships and collaborations
- Royalties distribution
- Start-up companies
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Profesor Ian Majewski
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Diana Hansen
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor James Vince
- Associate Professor Jason Tye-Din
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Kate Sutherland
- Associate Professor Leanne Robinson
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Misty Jenkins
- Associate Professor Nawaf Yassi
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Rosie Watson
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Sant-Rayn Pasricha
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Alisa Glukhova
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Brad Sleebs
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Jacqui Gulbis
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kelly Rogers
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Rory Bowden
- Dr Samir Taoudi
- Dr Shabih Shakeel
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Kaye Wycherley
- Keely Bumsted O'Brien
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Anne Voss
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor James McCarthy
- Professor Jane Visvader
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- A new regulator of stemness to create dendritic cell factories for immunotherapy
- Advanced methods for genomic rearrangement detection
- Control of cytokine signaling by SOCS1
- Defining the protein modifications associated with respiratory disease
- Delineating the pathways driving cancer development and therapy resistance
- Developing a new drug that targets plasmacytoid dendritic cells for the treatment of lupus
- Development and mechanism of action of novel antimalarials
- Development of a novel particle-based malaria vaccine
- Development of tau-specific therapeutic and diagnostic antibodies
- Discovering novel therapies for major human pathogens
- Dissecting host cell invasion by the diarrhoeal pathogen Cryptosporidium
- Epigenetic biomarkers of tuberculosis infection
- Essential role of glycobiology in malaria parasites
- Evolution of haematopoiesis in vertebrates
- Human lung protective immunity to tuberculosis
- Identifying novel treatment options for ovarian carcinosarcoma
- Interaction with Toxoplasma parasites and the brain
- Interactions between tumour cells and their microenvironment in non-small cell lung cancer
- Investigating the role of mutant p53 in cancer
- Microbiome strain-level analysis using long read sequencing
- Minimising rheumatic adverse events of checkpoint inhibitor cancer therapy
- Modelling spatial and demographic heterogeneity of malaria transmission risk
- Naturally acquired immune response to malaria parasites
- Predicting the effect of non-coding structural variants in cancer
- Structural basis of catenin-independent Wnt signalling
- Structure and biology of proteins essential for Toxoplasma parasite invasion
- T lymphocytes: how memories are made
- TICKER: A cell history recorder for longitudinal patient monitoring
- Targeting host pathways to develop new broad-spectrum antiviral drugs
- Targeting post-translational modifications to disrupting the function of secreted proteins
- Targeting the epigenome to rewire pro-allergic T cells
- Targeting the immune microenvironment to treat KRAS-mutant adenocarcinoma
- The E3 ubiquitin ligase Parkin and mitophagy in Parkinson’s disease
- The molecular controls on dendritic cell development
- Understanding malaria infection dynamics
- Understanding the genetics of neutrophil maturation
- Understanding the neuroimmune regulation of innate immunity
- Understanding the proteins that regulate programmed cell death at the molecular level
- Using cutting-edge single cell tools to understand the origins of cancer
- When healthy cells turn bad: how immune responses can transition to lymphoma
- School resources
- Frequently asked questions
- Student profiles
- Abebe Fola
- Andrew Baldi
- Anna Gabrielyan
- Bridget Dorizzi
- Casey Ah-Cann
- Catia Pierotti
- Emma Nolan
- Huon Wong
- Jing Deng
- Joy Liu
- Kaiseal Sarson-Lawrence
- Komal Patel
- Lilly Backshell
- Megan Kent
- Naomi Jones
- Rebecca Delconte
- Roberto Bonelli
- Rune Larsen
- Runyu Mao
- Sarah Garner
- Simona Seizova
- Wayne Cawthorne
- Wil Lehmann
- Miles Horton
- Alexandra Gurzau
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Bowel cancer

Australia has one of the highest rates of bowel cancer in the world. Each year, more than 16,000 Australians are diagnosed with bowel cancer. Many bowel cancers are detected at later, difficult to treat stages. If detected early, almost all cases of bowel cancer are curable. We are working to develop better early detection tests and to improve treatments for bowel cancer.

Understanding how these crypts and buds develop could help scientists understand what happens
when bowel cancer develops.
Our bowel cancer research
Our bowel cancer scientists and clinicians are working to improve the detection and treatment of bowel cancer by:
- Understanding the changes in healthy bowel cells that drive cancer formation.
- Deciphering how cancer cells 'communicate' with their environment to promote tumour growth.
- The role of bacterial infections and inflammation in cancer development.
- Developing better ways to detect and treat early-stage bowel cancer, including through a blood test.
- Discovering potential new treatments for bowel cancer.
- Matching people with bowel cancer to the best treatment for their disease.
What is bowel cancer?
Bowel cancer begins as an uncontrolled growth of cells in the walls of the bowel (the large intestine – the colon or the rectum). If untreated, the cancer can spread to other organs. Bowel cancer may also be called colon cancer or colorectal cancer.
Most bowel cancers arise from cells in the bowel lining called epithelial cells. These cells become cancerous after acquiring genetic changes that make them divide excessively and become long-lived.
Small non-cancerous growths in the bowel lining called ‘polyps’ often precede bowel cancer. Most polyps do not grow any further. Occasionally the cells in a polyp undergo changes that make them grow into a larger tumour. This can damage or block the bowel. ‘Metastatic’ or ‘secondary’ bowel cancer occurs when cancer cells spread beyond the bowel and travel to other parts of the body, where they grow as tumours.
Bowel development and cancer
Bowel cancers arise from the cells that line the bowel. They occur because the systems that normally control cell growth and survival have stopped working properly. Many processes that occur in bowel cancer cells are similar to those occurring during the development and growth of the bowel in embryos. Understanding how cell growth is controlled during bowel development is revealing what goes awry in bowel cancer.
Bowel cancer risk factors
Most bowel cancers arise ‘spontaneously’, with no predictable cause. Like many cancers, the risk of developing bowel cancer increases with age. About 92 per cent of people diagnosed with bowel cancer are over the age of 50.
Other risk factors for developing bowel cancer are:
- A history of developing polyps, or an earlier case of bowel, stomach or uterine cancer. These cancers may all be caused by similar cancer-causing gene abnormalities.
- Having relatives who had polyps or bowel cancer. People can be tested for inherited (familial) bowel cancer risk genes.
- Having inflammatory bowel disease, such as colitis or Crohn’s disease.
- A diet high in red meats, processed meats, fried foods or alcohol, or low in vegetables, fruit and whole grains.
- Being obese or physically inactive.
- Smoking.
How is bowel cancer detected?
The earliest, most treatable forms of bowel cancer generally have no symptoms. Clinical trials have shown that offering bowel cancer screening tests to people older than 50 years saves lives through early detection. Screening is a cost-effective way to detect bowel cancer at early and curable stages.
Currently, bowel cancer screening uses the faecal occult blood test (FOBT) that detects small amounts of blood in a stool (faeces) sample. Blood in stools is a possible sign of early bowel cancer.
When bowel cancer is suspected, the bowel lining can be examined by colonoscopy or sigmoidoscopy. In these, a flexible video camera is passed into the bowel through the anus. Samples from possible bowel cancer can be removed for microscopic diagnosis.
Some bowel cancers can also be detected using non-invasive imaging techniques such as ‘virtual colonoscopy’ or a magnetic resonance imaging (MRI) scan to create a three-dimensional image of the bowel. These techniques can miss polyps or small cancers that may be detected by colonoscopy and are currently considered inferior to a colonoscopy.
There is as yet no blood test that can reliably detect bowel cancer. Developing such a test is a goal of our bowel cancer researchers
For further information about bowel cancer detection please visit Bowel Cancer Australia.
How is bowel cancer treated?
Earlier diagnosis and better treatments have seen a doubling in survival rates from bowel cancer in Australia over the past 40 years.
When bowel cancer is detected early, before it has spread outside the bowel, it can often be cured by using surgery to remove the section of the bowel that contains the cancer.
When the cancer has spread outside the bowel (metastatic bowel cancer), surgery is usually combined with other treatments to kill any remaining cancer cells. Chemotherapy is an important part of treatment for metastatic bowel cancer. Several different chemotherapy drugs are used to treat bowel cancer, either alone or in combinations of two or more drugs.
Recently, some ‘monoclonal antibody’ treatments have been shown to be effective for treating bowel cancer. These contain antibodies that bind to proteins that are helping the bowel cancer to grow. This blocks the proteins’ function, preventing cancer growth. Monoclonal antibody treatments are sometimes combined with chemotherapy to increase their effect.
Bowel cancer treatment is currently hindered by a poor understanding of which patients will respond to which treatments. Genetic testing of bowel cancers is starting to reveal certain gene changes that predict whether a patient will respond well to a certain type of treatment. In particular, this testing can indicate whether monoclonal antibody treatments will be effective.
For more detailed information about bowel cancer treatment, please visit Bowel Cancer Australia.
WEHI researchers are not able to provide specific medical advice specific to individuals. If you have bowel cancer and wish to find out more information about clinical trials, please visit Australian Cancer Trials or the Australian New Zealand Clinical Trials Registry, or consult your medical specialist.
Researchers:
Super Content:
Clinician scientists Associate Professor Jeanne Tie and Associate Professor Sumitra Ananda are leading trials of a blood test to guide cancer treatment after surgery.
Our research into bowel development has suggested a new mechanism for how bowel cancer starts.
A collaborative research effort has offered new hope for treating bowel cancer.
Dr Tracy Putoczki speaks with ABC Radio AM about her team's discovery of a new target for anti cancer therapies
Our research has demonstrated a potential new way to treat two of the most common cancers worldwide.